Compare Amphastar Pharmaceuticals Inc (AMPH) vs NRG Energy Inc (NRG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs NRG Energy Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while NRG Energy Inc trades at $139.3 (market cap $29.63B). The key difference: NRG Energy Inc is far larger — about 35.9× Amphastar Pharmaceuticals Inc's market cap, and NRG Energy Inc pays a 1.35% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | NRG | |
|---|---|---|
Market Cap | $826.08M | $29.63B |
Sector | Health | Utilities |
52-Week High | $30.81 | $184.03 |
52-Week Low | $16.87 | $120.65 |
Enterprise Value | $1.22B | $53.46B |
Dividend Yield | — | 1.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
NRG Energy trades at $140.42, down 0.04% on the day, with a neutral technical signal and bullish moving averages. The stock shows strong analyst support with 64% buy ratings, but faces high valuation with a P/E of 154.31 and modest net income margin of 0.74%. Recent earnings beat expectations in Q3 and Q4 2025, but missed in Q1 2026, with Q2 2026 results pending. Cash flow from operations was $1.91 billion in 2025, though debt levels have risen significantly.
Outlook is mixed: robust revenue growth and strategic initiatives like the smart home segment offer upside, but elevated debt and margin pressures pose risks. The stock's performance hinges on upcoming Q2 earnings and execution on EBITDA guidance of $5.325–$5.825 billion for 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About NRG Energy Inc
NRG Energy is one of the largest retail energy providers in the U.S., with 7 million customers, including its 2021 acquisition of Direct Energy. It also is one of the largest U.S. independent power producers, with 16 gigawatts of nuclear, coal, gas, and oil power generation capacity primarily in Texas. Since 2018, NRG has divested its 47% stake in NRG Yield, among other renewable energy and conventional generation investments. NRG exited Chapter 11 bankruptcy as a stand-alone entity in December 2003.
Read more on NRG →
